文献速递肝病

NASH肝硬化患者纤维化逆转与临床结局改善相关

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
PubMed 文献 · Hepatology · 2022-02-07

该研究基于两项安慰剂对照试验的1135例代偿期NASH肝硬化患者,评估组织学和非侵入性纤维化检测与肝脏相关并发症的关联。中位随访16.6个月期间,6.3%患者发生肝脏相关事件;第48周肝硬化逆转(16%)与事件风险降低独立相关(HR 0.16,95%CI 0.04-0.65,p=0.0104)。

要点

  • NASH肝硬化患者中,组织学纤维化逆转与肝脏相关事件风险显著降低相关。
  • 基线肝胶原、α-SMA、机器学习纤维化参数、肝硬度及血清NITs升高与事件风险增加相关。
  • 组织学纤维化逆转和NITs可作为NASH肝硬化临床试验的终点指标。

核心结论

  • 在代偿期NASH肝硬化患者中,纤维化逆转与肝脏相关并发症减少相关。
  • 组织学纤维化逆转和NITs可作为NASH肝硬化临床试验的终点指标。

研究设计与样本

  • 两项安慰剂对照试验(simtuzumab和selonsertib)纳入代偿期NASH肝硬化患者,共1135例。
  • 基线及第48周通过NASH CRN和Ishak分类、机器学习方法评估纤维化,并量化肝胶原和α-SMA表达。
  • 采用瞬时弹性成像测肝硬度,计算血清NITs(ELF、NFS、FIB-4),Cox回归分析基线及变化与裁决的肝脏相关临床事件关联。

主要发现

  • 709例(62%)为Ishak 6期纤维化,ELF和肝硬度中位数分别为10.66和21.1 kPa。
  • 中位随访16.6个月,71例(6.3%)发生肝脏相关事件。
  • 基线Ishak 6期、较高肝胶原、α-SMA、机器学习纤维化参数、肝硬度、ELF、NFS和FIB-4与事件相关。
  • 第48周肝硬化逆转176例(16%),逆转者事件发生率1.1%(2/176),未逆转者7.2%(69/957),HR 0.16(95%CI 0.04-0.65,p=0.0104)。
  • 调整基线值后,肝胶原、α-SMA、机器学习纤维化参数、NFS和肝硬度增加与事件风险增加相关。

临床怎么用

  • 对于代偿期NASH肝硬化患者,组织学纤维化逆转和NITs改善可提示肝脏相关并发症风险降低。
  • 临床中可考虑将纤维化逆转和NITs作为NASH肝硬化治疗试验的评估终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver-related complications in patients with NASH cirrhosis. APPROACH AND RESULTS: Patients with compensated cirrhosis due to NASH were enrolled in two placebo-controlled trials of simtuzumab and selonsertib. Liver fibrosis at baseline and week 48 (W48) was staged by NASH Clinical Research Network (CRN) and Ishak classifications and a machine learning (ML) approach, hepatic collagen and alpha-smooth muscle actin (α-SMA) expression were quantified by morphometry, liver stiffness (LS) was measured by transient elastography, and serum NITs (enhanced liver fibrosis [ELF], NAFLD fibrosis score [NFS], and Fibrosis-4 index [FIB-4]) were calculated. Cox regression determined associations between these parameters at baseline and their changes over time with adjudicated liver-related clinical events. Among 1,135 patients, 709 (62%) had Ishak stage 6 fibrosis, and median ELF and LS were 10.66 and 21.1 kPa, respectively. During a median follow-up of 16.6 months, 71 (6.3%) had a liver-related event; associated baseline factors included Ishak stage 6 fibrosis, and higher hepatic collagen, α-SMA expression, ML-based fibrosis parameters, LS, ELF, NFS, and FIB-4. Cirrhosis regression observed in 16% (176/1,135) between BL and W48 was associated with a lower risk of events versus nonregression (1.1% [2/176] vs. 7.2% [69/957]; HR, 0.16; 95% CI, 0.04, 0.65 [p = 0.0104]). Conversely, after adjustment for baseline values, increases in hepatic collagen, α-SMA, ML-based fibrosis parameters, NFS, and LS were associated with an increased risk of events. CONCLUSIONS: In patients with compensated cirrhosis due to NASH, regression of fibrosis is associated with a reduction in liver-related complications. These data support the utility of histologic fibrosis regression and NITs as clinical trial endpoints for NASH cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022. PMID: 34662449. doi:10.1002/hep.32204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。